Elevated exhaustion levels and reduced functional dive may predict severe progression in COVID-19 patients

Cellular and Molecular Immunology

17, 541-543

DOI: 10.1038/s41423-020-0401-3

Citation Report

#	Article	IF	Citations
1	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. Oncologist, 2020, 25, e1562-e1573.	1.9	6
2	Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art. Frontiers in Immunology, 2020, 11, 577442.	2.2	27
3	Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics. International Immunopharmacology, 2020, 89, 107082.	1.7	23
4	From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infection, Genetics and Evolution, 2020, 85, 104502.	1.0	178
5	Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19. Nature Communications, 2020, 11, 5243.	5.8	138
6	Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection. Journal of Biomolecular Structure and Dynamics, 2022, 40, 1719-1735.	2.0	26
7	Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report. Journal of Medical Case Reports, 2020, 14, 187.	0.4	24
8	Cellâ€mediated and humoral adaptive immune responses to SARSâ€CoVâ€2 are lower in asymptomatic than symptomatic COVIDâ€19 patients. European Journal of Immunology, 2020, 50, 2013-2024.	1.6	53
9	SARS-CoV-2 infections in children and young people. Clinical Immunology, 2020, 220, 108588.	1.4	82
10	Characteristics of immune cells and cytokines in patients with coronavirus disease 2019 in Guangzhou, China. Human Immunology, 2020, 81, 702-708.	1.2	28
11	SARS-CoV-2 and coagulation disorders in different organs. Life Sciences, 2020, 260, 118431.	2.0	94
12	Severe COVID-19: what have we learned with the immunopathogenesis?. Advances in Rheumatology, 2020, 60, 50.	0.8	53
13	COVID-19 and cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188412.	3.3	4
14	Cardiac inflammation in COVID-19: Lessons from heart failure. Life Sciences, 2020, 260, 118482.	2.0	72
15	Immunology of COVIDâ€19 and diseaseâ€modifying therapies: the good, the bad and the unknown. European Journal of Neurology, 2020, 28, 3503-3516.	1.7	20
16	The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia. Journal of Neuroimmunology, 2020, 346, 577323.	1.1	21
17	Immune-mediated approaches against COVID-19. Nature Nanotechnology, 2020, 15, 630-645.	15.6	260
18	Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science, 2020, 369, .	6.0	1,280

#	Article	IF	Citations
19	Comprehensive mapping of immune perturbations associated with severe COVID-19. Science Immunology, 2020, 5, .	5.6	677
20	Increased CD95 (Fas) and PDâ€1 expression in peripheral blood T lymphocytes in COVIDâ€19 patients. British Journal of Haematology, 2020, 191, 207-211.	1.2	84
21	SARSâ€CoV2 and pregnancy: An invisible enemy?. American Journal of Reproductive Immunology, 2020, 84, e13308.	1.2	40
22	Vitamin D3 as Potential Treatment Adjuncts for COVID-19. Nutrients, 2020, 12, 3512.	1.7	39
23	The bioenergetics of COVID-19 immunopathology and the therapeutic potential of biophysical radiances. Journal of Photochemistry and Photobiology B: Biology, 2020, 213, 112083.	1.7	6
24	Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19. Immunity, 2020, 53, 1296-1314.e9.	6.6	278
25	SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors. Immunity, 2020, 53, 1245-1257.e5.	6.6	194
26	Clinical Features and Short-Term Outcomes in COVID-19-Infected Patients with Cancer . Cancer Management and Research, 2020, Volume 12, 12021-12028.	0.9	0
27	Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. Immunity, 2020, 53, 1258-1271.e5.	6.6	255
28	COVID-19: The Emerging Immunopathological Determinants for Recovery or Death. Frontiers in Microbiology, 2020, 11, 588409.	1.5	19
29	Age-related mitochondrial dysfunction as a key factor in COVID-19 disease. Experimental Gerontology, 2020, 142, 111147.	1.2	73
30	Absolute Eosinophil Count Predicts Intensive Care Unit Transfer Among Elderly COVID-19 Patients From General Isolation Wards. Frontiers in Medicine, 2020, 7, 585222.	1.2	10
31	Increased ILâ€10â€producing regulatory T cells are characteristic of severe cases of COVIDâ€19. Clinical and Translational Immunology, 2020, 9, e1204.	1.7	59
32	Updated information on new coronavirus disease 2019 occurrence, drugs, and prediction of a potential receptor. Journal of Biochemical and Molecular Toxicology, 2020, 34, e22594.	1.4	3
33	Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. International Immunopharmacology, 2020, 88, 106885.	1.7	30
34	Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Frontiers in Immunology, 2020, 11, 1949.	2.2	345
35	Promise and challenges in the development of COVID-19 vaccines. Human Vaccines and Immunotherapeutics, 2020, 16, 2604-2608.	1.4	31
36	COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduction and Targeted Therapy, 2020, 5, 128.	7.1	535

#	Article	IF	Citations
37	The COVID-19 Pandemic: Does Our Early Life Environment, Life Trajectory and Socioeconomic Status Determine Disease Susceptibility and Severity?. International Journal of Molecular Sciences, 2020, 21, 5094.	1.8	39
38	The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frontiers in Immunology, 2020, 11, 1817.	2.2	189
39	COVID-19: Complement, Coagulation, and Collateral Damage. Journal of Immunology, 2020, 205, 1488-1495.	0.4	127
40	Subcutaneous tocilizumab treatment in patients with severe COVID-19â€“related cytokine release syndrome: An observational cohort study. EClinicalMedicine, 2020, 24, 100410.	3.2	25
41	Coronavirus Disease of 2019: a Mimicker of Dengue Infection?. SN Comprehensive Clinical Medicine, 2020, 2, 1109-1119.	0.3	32
42	T cell responses in patients with COVID-19. Nature Reviews Immunology, 2020, 20, 529-536.	10.6	706
43	Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. Npj Vaccines, 2020, 5, 69.	2.9	121
44	The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. Frontiers in Immunology, 2020, 11, 1991.	2.2	124
45	The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. Life Sciences, 2020, 258, 118166.	2.0	79
46	Characteristics of laboratory findings of COVID-19 patients with comorbid diabetes mellitus. Diabetes Research and Clinical Practice, 2020, 167, 108351.	1.1	18
47	IL-6â€“based mortality risk model for hospitalized patients with COVID-19. Journal of Allergy and Clinical Immunology, 2020, 146, 799-807.e9.	1.5	154
48	Single-cell landscape of immunological responses in patients with COVID-19. Nature Immunology, 2020, 21, 1107-1118.	7.0	508
49	Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?. Cancers, 2020, 12, 2237.	1.7	71
50	Salt-dependent hypertension and inflammation: targeting the gutâ€“brain axis and the immune system with Brazilian green propolis. Inflammopharmacology, 2020, 28, 1163-1182.	1.9	10
51	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell, 2020, 183, 158-168.e14.	13.5	1,561
52	A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host. Frontiers in Cellular and Infection Microbiology, 2020, 10, 575404.	1.8	4
53	SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment. Frontiers in Immunology, 2020, 11, 570927.	2.2	28
54	SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite Preadaptation to the Low-CpG Environment in Humans. MBio, 2020, 11, .	1.8	106

#	Article	IF	Citations
55	The Current Recommended Drugs and Strategies for the Treatment of Coronavirus Disease (COVID-19) . Therapeutics and Clinical Risk Management, 2020, Volume 16, 933-946.	0.9	9
56	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. Frontiers in Immunology, 2020, 11, 562264.	2.2	8
57	Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19. Thrombosis and Haemostasis, 2020, 120, 1629-1641.	1.8	44
58	Immune Correlates of COVID-19 Control. Frontiers in Immunology, 2020, 11, 569611.	2.2	21
59	An Effective COVID-19 Vaccine Needs to Engage T Cells. Frontiers in Immunology, 2020, 11, 581807.	2.2	75
60	Cytokine storm and COVID-19: a chronicle of pro-inflammatory cytokines. Open Biology, 2020, 10, 200160.	1.5	232
61	Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies. Journal of Experimental Medicine, 2020, 217, .	4.2	55
62	Preliminary Exploration of the Cause of Liver Disorders During Early Stages in COVID-19 Patients. Frontiers in Medicine, 2020, 7, 501.	1.2	3
63	Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses. Human Vaccines and Immunotherapeutics, 2020, 16, 2980-2991.	1.4	24
64	COVID-19: In the Eye of the Cytokine Storm. Frontiers in Immunology, 2020, 11, 558898.	2.2	107
65	Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and â€œNew Old Friendsâ€• Frontiers in Immunology, 2020, 11, 2059.	2.2	18
66	Complex Immunometabolic Profiling Reveals the Activation of Cellular Immunity and Biliary Lesions in Patients with Severe COVID-19. Journal of Clinical Medicine, 2020, 9, 3000.	1.0	2
67	Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19. Medical Hypotheses, 2020, 144, 110161.	0.8	22
68	Immunological features of coronavirus disease 2019 in patients with cancer. European Journal of Cancer, 2020, 139, 70-80.	1.3	13
69	Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. Science Immunology, 2020, 5, .	5.6	198
70	T cell response in patients with COVID-19. Blood Science, 2020, 2, 76-78.	0.4	22
71	Friends or foes? The knowns and unknowns of natural killer cell biology in COVID-19 and other coronaviruses in July 2020. PLoS Pathogens, 2020, 16, e1008820.	2.1	21
72	Implication of Aging Related Chronic Neuroinflammation on COVID-19 Pandemic. Journal of Personalized Medicine, 2020, 10, 102.	1.1	21

#	Article	IF	Citations
73	Obesity is a potential risk factor contributing to clinical manifestations of COVID-19. International Journal of Obesity, 2020, 44, 2479-2485.	1.6	47
74	SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. Shock, 2020, 54, 416-437.	1.0	41
75	The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections. Frontiers in Immunology, 2020, 11, 2033.	2.2	69
76	Storm of soluble immune checkpoints associated with disease severity of COVID-19. Signal Transduction and Targeted Therapy, 2020, 5, 192.	7.1	38
77	Suboptimal SARS-CoV-2â˜specific CD8 ⁺ T cell response associated with the prominent HLA-A*02:01 phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24384-24391.	3.3	168
78	Obesity, noncommunicable diseases, and <scp>COVID</scp>â€19: A perfect storm. American Journal of Human Biology, 2020, 32, e23484.	0.8	21
79	Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19). Journal of Molecular Medicine, 2020, 98, 1369-1383.	1.7	30
80	Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019. , 2020, 2, e0178.		34
81	Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19. Scientific Reports, 2020, 10, 21697.	1.6	65
82	Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension. Frontiers in Immunology, 2020, 11, 596684.	2.2	20
83	Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology. Frontiers in Cardiovascular Medicine, 2020, 7, 568720.	1.1	5
84	Will SARS-CoV-2 Infection Elicit Long-Lasting Protective or Sterilising Immunity? Implications for Vaccine Strategies (2020). Frontiers in Immunology, 2020, 11, 571481.	2.2	48
85	Akt-Fas to Quell Aberrant T Cell Differentiation and Apoptosis in Covid-19. Frontiers in Immunology, 2020, 11, 600405.	2.2	15
86	Biomodulina T (InmunyVitalÂ®) Restores T Cells and Helps Contain COVID-19. Frontiers in Immunology, 2020, 11, 606447.	2.2	4
87	Hyperinflammation and Immune Response Generation in COVID-19. NeuroImmunoModulation, 2020, 27, 80-86.	0.9	41
88	Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System. Frontiers in Immunology, 2020, 11, 596631.	2.2	79
89	Vaccine-Induced CD8+ T Cell Responses in Children: A Review of Age-Specific Molecular Determinants Contributing to Antigen Cross-Presentation. Frontiers in Immunology, 2020, 11, 607977.	2.2	14
90	Temporal changes in laboratory markers of survivors and non-survivors of adult inpatients with COVID-19. BMC Infectious Diseases, 2020, 20, 952.	1.3	60

#	Article	IF	Citations
91	Rapid detection of SARSâ€CoVâ€2â€specific memory Tâ€cell immunity in recovered COVIDâ€19 cases. Clinical and Translational Immunology, 2020, 9, e1219.	1.7	21
92	Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection. Nature Communications, 2020, 11, 6319.	5.8	203
93	Management of immune checkpoint therapy for patients with cancer in the face of COVID-19. , 2020, 8, e001593.		4
94	Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2. Pathogens, 2020, 9, 1027.	1.2	20
95	Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?. Frontiers in Immunology, 2020, 11, 573662.	2.2	42
96	The Impact of Obesity and Lifestyle on the Immune System and Susceptibility to Infections Such as COVID-19. Frontiers in Nutrition, 2020, 7, 597600.	1.6	57
97	Recent advances in vaccine and immunotherapy for COVID-19. Human Vaccines and Immunotherapeutics, 2020, 16, 3011-3022.	1.4	34
98	Elevated Exhaustion Levels of NK and CD8+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease. Frontiers in Immunology, 2020, 11, 580237.	2.2	96
99	CD4 and CD8 Lymphocyte Counts as Surrogate Early Markers for Progression in SARS-CoV-2 Pneumonia: A Prospective Study. Viruses, 2020, 12, 1277.	1.5	17
100	Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmunity Reviews, 2020, 19, 102567.	2.5	521
101	Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis. International Journal of Infectious Diseases, 2020, 96, 131-135.	1.5	373
102	Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?. Frontiers in Immunology, 2020, 11, 1229.	2.2	105
103	The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: A sentinel?. Clinica Chimica Acta, 2020, 508, 122-129.	0.5	62
104	Development of an inactivated vaccine candidate for SARS-CoV-2. Science, 2020, 369, 77-81.	6.0	1,180
105	Immune response to SARSâ€CoVâ€2 and mechanisms of immunopathological changes in COVIDâ€19. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1564-1581.	2.7	828
106	Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients. Clinical Immunology, 2020, 217, 108486.	1.4	135
107	Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19. Clinical Immunology, 2020, 216, 108464.	1.4	81
108	An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019. Clinical Infectious Diseases, 2020, 71, 2272-2275.	2.9	91

#	Article	IF	Citations
109	Immunology of COVID-19: Current State of the Science. Immunity, 2020, 52, 910-941.	6.6	1,387
110	Lymphopenia in COVIDâ€19: Therapeutic opportunities. Cell Biology International, 2020, 44, 1792-1797.	1.4	243
111	Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications. Pharmacological Research, 2020, 159, 104946.	3.1	26
112	Mechanistic inferences from clinical reports of SARS-CoV-2. Infectious Diseases, 2020, 52, 527-537.	1.4	4
113	A Comprehensive Updated Review on SARSâ€CoVâ€2 and COVIDâ€19. Journal of Clinical Pharmacology, 2020, 60, 954-975.	1.0	14
114	Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. International Immunopharmacology, 2020, 85, 106688.	1.7	67
115	Dysregulation of the immune response affects the outcome of critical COVIDâ€19 patients. Journal of Medical Virology, 2020, 92, 2768-2776.	2.5	41
116	A summary of the diagnostic and prognostic value of hemocytometry markers in COVID-19 patients. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 415-431.	2.7	58
117	Targeting the NLRP3 Inflammasome in Severe COVID-19. Frontiers in Immunology, 2020, 11, 1518.	2.2	329
118	Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. European Journal of Cancer, 2020, 135, 62-65.	1.3	32
119	Diacerein: A potential multi-target therapeutic drug for COVID-19. Medical Hypotheses, 2020, 144, 109920.	0.8	27
120	Is herpes zoster being an indicator for <scp>COVID</scp> 19 infection?. Dermatologic Therapy, 2020, 33, e13846.	0.8	5
121	Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. Frontiers in Immunology, 2020, 11, 1606.	2.2	43
122	Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19. Open Forum Infectious Diseases, 2020, 7, ofaa242.	0.4	62
123	Dengue Fever, <scp>COVID</scp>â€19 (<scp>SARSâ€CoV</scp>â€2), and <scp>Antibodyâ€Dependent</scp> Enhancement (<scp>ADE</scp>): A Perspective. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 97, 662-667.	1.1	89
124	Inflammation, Immunity and Immunogenetics in COVID-19: A Narrative Review. Indian Journal of Clinical Biochemistry, 2020, 35, 260-273.	0.9	46
125	Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. Journal of Leukocyte Biology, 2020, 108, 17-41.	1.5	573
126	Herpes zoster cases increased during COVID-19 outbreak. Is it possible a relation?. Journal of Dermatological Treatment, 2022, 33, 1180-1180.	1.1	13

#	Article	IF	Citations
127	Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease. Immunity, 2020, 53, 442-455.e4.	6.6	281
128	Metabolic Syndrome and COVID 19: Endocrine-Immune-Vascular Interactions Shapes Clinical Course. Endocrinology, 2020, 161, .	1.4	80
129	Telomeres and COVIDâ€19. FASEB Journal, 2020, 34, 7247-7252.	0.2	59
130	Cell-Mediated Immune Responses to COVID-19 Infection. Frontiers in Immunology, 2020, 11, 1662.	2.2	48
131	Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nature Communications, 2020, 11, 3434.	5.8	636
132	Hematological manifestations of COVID-19. Leukemia and Lymphoma, 2020, 61, 2790-2798.	0.6	30
133	Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection. Reviews in Medical Virology, 2020, 30, e2123.	3.9	69
134	Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients. Cellular and Molecular Immunology, 2020, 17, 878-880.	4.8	45
135	Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Science Immunology, 2020, 5, .	5.6	689
136	Long-term infection of SARS-CoV-2 changed the body's immune status. Clinical Immunology, 2020, 218, 108524.	1.4	33
137	The trinity of COVID-19: immunity, inflammation and intervention. Nature Reviews Immunology, 2020, 20, 363-374.	10.6	3,347
138	High-dimensional immune profiling by mass cytometry revealed immunosuppression and dysfunction of immunity in COVID-19 patients. Cellular and Molecular Immunology, 2020, 17, 650-652.	4.8	110
139	Rethinking the role of hydroxychloroquine in the treatment of COVIDâ€19. FASEB Journal, 2020, 34, 6027-6037.	0.2	110
140	Immunotherapies for COVID-19: lessons learned from sepsis. Lancet Respiratory Medicine,the, 2020, 8, 946-949.	5.2	111
141	Hematological findings and complications of <scp>COVID</scp>â€19. American Journal of Hematology, 2020, 95, 834-847.	2.0	1,354
142	Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD. Inflammatory Bowel Diseases, 2020, 26, 797-808.	0.9	133
143	Correspondence: Importance of the validated serum biochemistry and hemogram parameters for rapid diagnosis and to prevent false negative results during COVIDâ€19 pandemic. Biotechnology and Applied Biochemistry, 2021, 68, 390-391.	1.4	9
144	NLR: A Cost-effective Nomogram to Guide Therapeutic Interventions in COVID-19. Immunological Investigations, 2021, 50, 92-100.	1.0	35

#	Article	IF	Citations
145	BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy. Journal of Leukocyte Biology, 2021, 109, 49-53.	1.5	26
146	Excavating SARSâ€coronavirus 2 genome for epitopeâ€based subunit vaccine synthesis using immunoinformatics approach. Journal of Cellular Physiology, 2021, 236, 1131-1147.	2.0	20
147	Clinical Outcomes and Immunologic Characteristics of Coronavirus Disease 2019 in People With Human Immunodeficiency Virus. Journal of Infectious Diseases, 2021, 223, 403-408.	1.9	76
148	Obesity and diabetes as highâ€risk factors for severe coronavirus disease 2019 (<scp>Covid</scp>â€19). Diabetes/Metabolism Research and Reviews, 2021, 37, e3377.	1.7	352
149	High-dimensional single-cell analysis reveals the immune characteristics of COVID-19. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 320, L84-L98.	1.3	22
150	T-cell dysregulation in COVID-19. Biochemical and Biophysical Research Communications, 2021, 538, 204-210.	1.0	50
151	Can BCG vaccine protect against COVIDâ€19 via trained immunity and tolerogenesis?. BioEssays, 2021, 43, e2000200.	1.2	9
152	Response to: Letter to the Editor on â€œBonafÃ¨ M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Revâ€•by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella. Cytokine and Growth Factor Reviews, 2021, 58, 141-143.	3.2	9
153	Predictors of <scp>COVID</scp>â€19 severity: A literature review. Reviews in Medical Virology, 2021, 31, 1-10.	3.9	593
154	COVIDâ€19 in people living with HIV: Clinical implications of dynamics of the immune response to SARSâ€CoVâ€2. Journal of Medical Virology, 2021, 93, 1796-1804.	2.5	38
155	T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochemical and Biophysical Research Communications, 2021, 538, 211-217.	1.0	88
156	COVIDâ€19 and hematology findings based on the current evidences: A puzzle with many missing pieces. International Journal of Laboratory Hematology, 2021, 43, 160-168.	0.7	53
157	T Cells: Warriors of SARS-CoV-2 Infection. Trends in Immunology, 2021, 42, 18-30.	2.9	142
158	A systematic metaâ€analysis of immune signatures in patients with COVIDâ€19. Reviews in Medical Virology, 2021, 31, e2195.	3.9	38
159	Potential of algal metabolites for the development of broadâ€spectrum antiviral therapeutics: Possible implications in COVID â€19 therapy. Phytotherapy Research, 2021, 35, 2296-2316.	2.8	11
160	Pentoxifylline decreases serum LDH levels and increases lymphocyte count in COVID-19 patients: Results from an external pilot study. International Immunopharmacology, 2021, 90, 107209.	1.7	15
161	The emerging role of microRNAs in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. International Immunopharmacology, 2021, 90, 107204.	1.7	65
162	A mini-review on the effects of COVID-19 on younger individuals. Experimental Biology and Medicine, 2021, 246, 293-297.	1.1	40

#	Article	IF	Citations
163	Dysregulation of the immune response in coronavirus disease 2019. Cell Biology International, 2021, 45, 702-707.	1.4	41
164	Pathological and molecular examinations of postmortem testis biopsies reveal SARS-CoV-2 infection in the testis and spermatogenesis damage in COVID-19 patients. Cellular and Molecular Immunology, 2021, 18, 487-489.	4.8	115
165	PD-1-Expressing SARS-CoV-2-Specific CD8+ T Cells Are Not Exhausted, but Functional in Patients with COVID-19. Immunity, 2021, 54, 44-52.e3.	6.6	184
166	Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. Immunity, 2021, 54, 164-175.e6.	6.6	119
167	Impact of COVID-19 in solid organ transplant recipients. American Journal of Transplantation, 2021, 21, 925-937.	2.6	98
168	Harnessing the non-specific immunogenic effects of available vaccines to combat COVID-19. Human Vaccines and Immunotherapeutics, 2021, 17, 1650-1661.	1.4	12
169	Deciphering the COVIDâ€19 cytokine storm: Systematic review and metaâ€analysis. European Journal of Clinical Investigation, 2021, 51, e13429.	1.7	176
170	T cell immunobiology and cytokine storm of COVIDâ€19. Scandinavian Journal of Immunology, 2021, 93, e12989.	1.3	77
171	Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19. Cytokine and Growth Factor Reviews, 2021, 58, 32-48.	3.2	18
172	Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature. Cancer Investigation, 2021, 39, 9-14.	0.6	12
173	How the Covid-19 epidemic is challenging our practice in clinical nutritionâ€"feedback from the field. European Journal of Clinical Nutrition, 2021, 75, 407-416.	1.3	42
174	Beyond dexamethasone, emerging immunoâ€thrombotic therapies for COVIDâ€19. British Journal of Clinical Pharmacology, 2021, 87, 845-857.	1.1	6
175	Tâ€cell responses and therapies against SARSâ€CoVâ€2 infection. Immunology, 2021, 162, 30-43.	2.0	159
176	Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications. Molecular Neurobiology, 2021, 58, 106-117.	1.9	32
177	Antibody Responses and Clinical Outcomes in Adults Hospitalized With Severe Coronavirus Disease 2019 (COVID-19): A Post hoc Analysis of LOTUS China Trial. Clinical Infectious Diseases, 2021, 72, e545-e551.	2.9	34
178	COVID-19: Imbalanced Immune Responses and Potential Immunotherapies. Frontiers in Immunology, 2020, 11, 607583.	2.2	12
179	Immune-Based Therapy for COVID-19. Advances in Experimental Medicine and Biology, 2021, 1318, 449-468.	0.8	16
180	Role of the Immune Microenvironment in SARS-CoV-2 Infection. Cell Transplantation, 2021, 30, 096368972110106.	1.2	10

#	Article	IF	Citations
181	A digitized catalog of COVIDâ€19 epidemiology data. Quantitative Biology, 2021, 9, 23-46.	0.3	0
182	HLA and immunodominance in viral infection: T-cell responses in protection and immunopathogenesis. Microbiology Australia, 2021, 42, 84-86.	0.1	3
183	Clinical characteristics and predictive value of lower CD4+T cell level in patients with moderate and severe COVID-19: a multicenter retrospective study. BMC Infectious Diseases, 2021, 21, 57.	1.3	24
184	Illuminating the immunopathology of <scp>SARSâ€CoV</scp>â€2. Cytometry Part B - Clinical Cytometry, 2021, 100, 33-41.	0.7	11
185	Does Angiotensin II Peak in Response to SARS-CoV-2?. Frontiers in Immunology, 2020, 11, 577875.	2.2	11
186	Sex Hormones and Lung Inflammation. Advances in Experimental Medicine and Biology, 2021, 1304, 259-321.	0.8	29
187	High levels of soluble CD25 in COVIDâ€19 severity suggest a divergence between antiâ€viral and proâ€inflammatory Tâ€cell responses. Clinical and Translational Immunology, 2021, 10, e1251.	1.7	22
188	Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development. BioMed Research International, 2021, 2021, 1-11.	0.9	15
189	The immune response in bacterial and viral infectious diseases. Medic Ro, 2021, 3, 20.	0.0	0
190	COVID-19: Integrating the Complexity of Systemic and Pulmonary Immunopathology to Identify Biomarkers for Different Outcomes. Frontiers in Immunology, 2020, 11, 599736.	2.2	16
191	Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm. Cardiovascular Drugs and Therapy, 2021, 35, 231-247.	1.3	22
192	Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19. Frontiers in Pharmacology, 2020, 11, 583777.	1.6	73
193	The Immune Response and Effectiveness of COVID-19 Therapies. Advances in Experimental Medicine and Biology, 2021, 1321, 115-126.	0.8	6
194	Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study. Cancers, 2021, 13, 471.	1.7	87
195	Immune dysregulation and system pathology in COVID-19. Virulence, 2021, 12, 918-936.	1.8	74
196	Immune response to COVID-19 infection: a double-edged sword. Immunological Medicine, 2021, 44, 187-196.	1.4	14
197	Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles. ACS Nano, 2021, 15, 9627-9637.	7.3	66
198	Return to Work: Managing Employee Population Health During the COVID-19 Pandemic. Population Health Management, 2021, 24, S-3-S-15.	0.8	13

#	Article	IF	Citations
199	Immunological Characteristics of Non-Intensive Care Hospitalized COVID-19 Patients: A Preliminary Report. Journal of Clinical Medicine, 2021, 10, 849.	1.0	6
200	The COVID-19 Pandemic: an Appraisal of its Impact on Human Immunodeficiency Virus Infection and Pre-Eclampsia. Current Hypertension Reports, 2021, 23, 9.	1.5	10
201	B cell depletion and signs of sepsis-acquired immunodeficiency in bone marrow and spleen of COVID-19 deceased. International Journal of Infectious Diseases, 2021, 103, 628-635.	1.5	11
202	SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study. , 2021, 9, e001694.		23
203	T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression. Frontiers in Cellular and Infection Microbiology, 2021, 11, 624483.	1.8	110
204	Ageâ€related differences in the immune response could contribute to determine the spectrum of severity of COVIDâ€19. Immunity, Inflammation and Disease, 2021, 9, 331-339.	1.3	54
205	Elevated frequencies of CD14+HLA-DRlo/neg MDSCs in COVID-19 patients. Aging, 2021, 13, 6236-6246.	1.4	19
206	CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients. Cell Stress and Chaperones, 2021, 26, 515-525.	1.2	15
207	Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 Patients. Frontiers in Immunology, 2021, 12, 603563.	2.2	29
208	Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. Cell Host and Microbe, 2021, 29, 222-235.e4.	5.1	145
209	SARS-CoV-2 infection: Understanding the immune system abnormalities to get an adequate diagnosis. Bosnian Journal of Basic Medical Sciences, 2021, 21, 503-514.	0.6	3
211	T Cell Phenotyping in Individuals Hospitalized with COVID-19. Journal of Immunology, 2021, 206, 1478-1482.	0.4	12
213	Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology. Current Drug Targets, 2021, 22, 254-281.	1.0	27
214	Comparison of Selected Characteristics of SARS-CoV-2, SARS-CoV, and HCoV-NL63. Applied Sciences (Switzerland), 2021, 11, 1497.	1.3	5
216	Comorbidities and inflammation associated with ovarian cancer and its influence on SARS-CoV-2 infection. Journal of Ovarian Research, 2021, 14, 39.	1.3	5
217	The Immunopathology of COVID-19 and the Cannabis Paradigm. Frontiers in Immunology, 2021, 12, 631233.	2.2	25
218	Murine-Î²-coronavirus-induced neuropathogenesis sheds light on CNS pathobiology of SARS-CoV2. Journal of NeuroVirology, 2021, 27, 197-216.	1.0	11
219	Prediction of COVID-19 severity using laboratory findings on admission: informative values, thresholds, ML model performance. BMJ Open, 2021, 11, e044500.	0.8	35

#	Article	IF	Citations
220	The Inflammatory Factors Associated with Disease Severity to Predict COVID-19 Progression. Journal of Immunology, 2021, 206, 1597-1608.	0.4	60
221	Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. ImmunoTargets and Therapy, 2021, Volume 10, 63-85.	2.7	40
223	Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic. , 2021, 9, e002087.		7
224	Risk stratification by long nonâ€coding RNAs profiling in COVIDâ€19 patients. Journal of Cellular and Molecular Medicine, 2021, 25, 4753-4764.	1.6	34
225	Immune responses to SARS-CoV-2 infection in Humans and ACE2 humanized mice. Fundamental Research, 2021, 1, 124-130.	1.6	5
226	Immune Response Failure in Paucisymptomatic Long-Standing SARS-CoV-2 Spreaders. Clinics and Practice, 2021, 11, 151-161.	0.6	2
227	Epithelial response to IFNâ€Î³ promotes SARSâ€CoVâ€2 infection. EMBO Molecular Medicine, 2021, 13, e13191.	3.3	62
228	Risk Factors and Prognosis in Patients with COVID-19 and Liver Injury: A Retrospective Analysis. Journal of Multidisciplinary Healthcare, 2021, Volume 14, 629-637.	1.1	11
229	Profiling of the immune repertoire in COVID-19 patients with mild, severe, convalescent, or retesting-positive status. Journal of Autoimmunity, 2021, 118, 102596.	3.0	27
230	SARS-CoV-2 - SYNOPTIC CHART OF THE MAIN CHARACTERISTICS OF VIRUS, PATHOGENESIS, IMMUNE RESPONSE, IMMUNOPROPHYLAXIS. Roumanian Archives of Microbiology and Immunology, 2021, 80, 51-80.	0.1	1
231	Clinical Characteristics of Paediatric Hyperinflammatory Syndrome in the Era of Corona Virus Disease 2019 (COVID-19). Indian Journal of Clinical Biochemistry, 2021, 36, 404-415.	0.9	4
232	An Overview of a Year with COVID-19: What We Know?. Electronic Journal of General Medicine, 2021, 18, em286.	0.3	2
233	Current progress and challenges in the design and development of a successful COVID-19 vaccine. Fundamental Research, 2021, 1, 139-150.	1.6	19
234	Impact of SARS-CoV-2 on the clinical outcomes and placental pathology of pregnant women and their infants: A systematic review. Heliyon, 2021, 7, e06393.	1.4	24
235	Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. Frontiers in Immunology, 2021, 12, 589095.	2.2	102
237	COVID-19-associated secondary hemophagocytic lymphohistiocytosis (cytokine storm syndrome). Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 2021, 76, 51-66.	0.2	11
238	Utilization of C-Reactive Protein Test as a Predictor of Lung Injury in Patients with Coronavirus Disease 2019. Laboratory Medicine Online, 2021, 11, 81-87.	0.0	0
239	Development and validation of an individualized nomogram for early prediction of the duration of SARS-CoV-2 shedding in COVID-19 patients with non-severe disease. Journal of Zhejiang University: Science B, 2021, 22, 318-329.	1.3	6

#	Article	IF	Citations
240	Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome. Critical Care, 2021, 25, 140.	2.5	27
241	Analysis of the Long-Term Impact on Cellular Immunity in COVID-19-Recovered Individuals Reveals a Profound NKT Cell Impairment. MBio, 2021, 12, .	1.8	36
242	Upregulation of CCR4 in activated CD8⁺ T cells indicates enhanced lung homing in patients with severe acute SARSâ€CoVâ€2 infection. European Journal of Immunology, 2021, 51, 1436-1448.	1.6	22
243	Interleukin 6, soluble interleukin 2 receptor alpha (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 pneumonia. Cytokine, 2021, 140, 155438.	1.4	44
244	Identification of SARS-CoV-2 CTL epitopes for development of a multivalent subunit vaccine for COVID-19. Infection, Genetics and Evolution, 2021, 89, 104712.	1.0	9
245	Animal Models of COVID-19 II. Comparative Immunology. ILAR Journal, 2021, 62, 17-34.	1.8	20
246	Intermittent Hypoxic Preconditioning: A Potential New Powerful Strategy for COVID-19 Rehabilitation. Frontiers in Pharmacology, 2021, 12, 643619.	1.6	7
247	Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing. Heliyon, 2021, 7, e06836.	1.4	11
248	Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines. Immunological Investigations, 2021, 50, 743-779.	1.0	16
249	Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology, 2021, 60, SI90-SI95.	0.9	122
250	SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis. Life Sciences, 2021, 270, 119124.	2.0	57
251	Involvement of Interleukin-1 Receptor-Associated Kinase 4 and Interferon Regulatory Factor 5 in the Immunopathogenesis of SARS-CoV-2 Infection: Implications for the Treatment of COVID-19. Frontiers in Immunology, 2021, 12, 638446.	2.2	9
252	A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). Immunologic Research, 2021, 69, 213-224.	1.3	27
253	Influence of aging on T cell response and renin-angiotensin system imbalance during SARS-CoV-2 infection. Immunology Letters, 2021, 232, 35-38.	1.1	0
254	Endothelial cell, myeloid, and adaptive immune responses in SARSâ€CoVâ€2 infection. FASEB Journal, 2021, 35, e21577.	0.2	13
255	Longitudinal Peripheral Blood Transcriptional Analysis Reveals Molecular Signatures of Disease Progression in COVID-19 Patients. Journal of Immunology, 2021, 206, 2146-2159.	0.4	25
256	Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates. Virologica Sinica, 2021, 36, 879-889.	1.2	17
258	Immune Profile in Patients With COVID-19: Lymphocytes Exhaustion Markers in Relationship to Clinical Outcome. Frontiers in Cellular and Infection Microbiology, 2021, 11, 646688.	1.8	47

#	Article	IF	Citations
260	Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview. International Immunopharmacology, 2021, 93, 107364.	1.7	54
261	The Mechanisms and Animal Models of SARS-CoV-2 Infection. Frontiers in Cell and Developmental Biology, 2021, 9, 578825.	1.8	20
262	Immunosuppression as a Hallmark of Critical COVID-19: Prospective Study. Cells, 2021, 10, 1293.	1.8	20
263	Metabolic Defects of Peripheral T Cells in COVID-19 Patients. Journal of Immunology, 2021, 206, 2900-2908.	0.4	17
264	Cytokines and Leukocytes Subpopulations Profile in SARS-CoV-2 Patients Depending on the CT Score Severity. Viruses, 2021, 13, 880.	1.5	13
265	Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies. Scientific Reports, 2021, 11, 10220.	1.6	12
266	Adaptive immune responses to SARS-CoV-2. Advanced Drug Delivery Reviews, 2021, 172, 1-8.	6.6	6
267	Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study. Clinical Immunology, 2021, 226, 108712.	1.4	19
268	The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Molecular Cancer, 2021, 20, 76.	7.9	42
269	Adenosine-related small molecules show utility of recall antigen assay to screen compounds for off-target effects on memory T cells. Scientific Reports, 2021, 11, 9561.	1.6	1
270	Characteristics of mental health implications and plasma metabolomics in patients recently recovered from COVID-19. Translational Psychiatry, 2021, 11, 307.	2.4	15
271	A Pandemic within Other Pandemics. When a Multiple Infection of a Host Occurs: SARS-CoV-2, HIV and Mycobacterium tuberculosis. Viruses, 2021, 13, 931.	1.5	8
272	The Symptoms and Clinical Manifestations Observed in COVID-19 Patients/Long COVID-19 Symptoms that Parallel Toxoplasma gondii Infections. Journal of NeuroImmune Pharmacology, 2021, 16, 513-516.	2.1	13
273	Immune profiling of COVID-19: preliminary findings and implications for the pandemic. , 2021, 9, e002550.		15
274	Lymphopenia in COVID-19: Î³Î´ T Cells-Based Therapeutic Opportunities. Vaccines, 2021, 9, 562.	2.1	5
276	Can COVID-19 Increase the Risk of Herpes Zoster? A Narrative Review. Dermatology and Therapy, 2021, 11, 1119-1126.	1.4	43
277	Explaining machine learning based diagnosis of COVID-19 from routine blood tests with decision trees and criteria graphs. Computers in Biology and Medicine, 2021, 132, 104335.	3.9	58
278	Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation. Npj Vaccines, 2021, 6, 71.	2.9	23

#	Article	IF	Citations
279	SARS-CoV-2 Infection: Differences in Hematological Parameters Between Adults and Children. International Journal of General Medicine, 2021, Volume 14, 3035-3047.	0.8	10
280	Duration of post-COVID-19 symptoms are associated with sustained SARS-CoV-2 specific immune responses. JCI Insight, 2021, 6, .	2.3	31
281	Mathematical Model of Antiviral Immune Response against the COVID-19 Virus. Mathematics, 2021, 9, 1356.	1.1	11
283	Vitamin A Plasma Levels in COVID-19 Patients: A Prospective Multicenter Study and Hypothesis. Nutrients, 2021, 13, 2173.	1.7	40
284	Immune characterization of a Colombian family cluster with SARS-CoV-2 infection. Biomedica, 2021, 41, 86-102.	0.3	2
285	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. Microorganisms, 2021, 9, 1389.	1.6	4
286	Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19. Frontiers in Immunology, 2021, 12, 686029.	2.2	152
287	Relationship of SARS-CoV-2â€“specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection. Journal of Clinical Investigation, 2021, 131, .	3.9	113
288	COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. , 2021, 9, e002630.		76
289	Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review). Sovremennye Tehnologii V Medicine, 2021, 13, 81.	0.4	4
290	Alterations in T and B cell function persist in convalescent COVID-19 patients. Med, 2021, 2, 720-735.e4.	2.2	87
291	Lung-Centric Inflammation of COVID-19: Potential Modulation by Vitamin D. Nutrients, 2021, 13, 2216.	1.7	15
292	Systems Immunology Analysis Reveals the Contribution of Pulmonary and Extrapulmonary Tissues to the Immunopathogenesis of Severe COVID-19 Patients. Frontiers in Immunology, 2021, 12, 595150.	2.2	18
293	Phenotypes and Functions of SARS-CoV-2-Reactive T Cells. Molecules and Cells, 2021, 44, 401-407.	1.0	16
294	Environmental pollution and diabetes mellitus. World Journal of Meta-analysis, 2021, 9, 234-256.	0.1	1
295	Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. Journal of Experimental Medicine, 2021, 218, .	4.2	139
296	Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2-specific T-cells. European Respiratory Journal, 2022, 59, 2100285.	3.1	14
297	Dose-Related Aberrant Inhibition of Intracellular Perforin Expression by S1 Subunit of Spike Glycoprotein That Contains Receptor-Binding Domain from SARS-CoV-2. Microorganisms, 2021, 9, 1303.	1.6	2

#	Article	IF	Citations
298	Critical COVIDâ€19 is associated with distinct leukocyte phenotypes and transcriptome patterns. Journal of Internal Medicine, 2021, 290, 677-692.	2.7	20
299	Machine learning predictive model for severe COVID-19. Infection, Genetics and Evolution, 2021, 90, 104737.	1.0	28
301	COVID-19, Neuropathology, and Aging: SARS-CoV-2 Neurological Infection, Mechanism, and Associated Complications. Frontiers in Aging Neuroscience, 2021, 13, 662786.	1.7	18
302	COVID-19: Lung-Centric Immunothrombosis. Frontiers in Cellular and Infection Microbiology, 2021, 11, 679878.	1.8	21
303	SARS-CoV-2 infection paralyzes cytotoxic and metabolic functions of the immune cells. Heliyon, 2021, 7, e07147.	1.4	15
304	The Quality of SARS-CoV-2â€“Specific T Cell Functions Differs in Patients with Mild/Moderate versus Severe Disease, and T Cells Expressing Coinhibitory Receptors Are Highly Activated. Journal of Immunology, 2021, 207, 1099-1111.	0.4	34
306	Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors. , 2021, 9, e002835.		11
307	Single-Cell Transcriptomic Profiling of MAIT Cells in Patients With COVID-19. Frontiers in Immunology, 2021, 12, 700152.	2.2	22
308	Cell therapy in patients with COVID-19 using Whartonâ€™s jelly mesenchymal stem cells: a phase 1 clinical trial. Stem Cell Research and Therapy, 2021, 12, 410.	2.4	57
309	SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. PLoS Pathogens, 2021, 17, e1009761.	2.1	66
310	A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. Current Medical Science, 2021, 41, 1037-1051.	0.7	136
311	Virological and immunological features of SARSâ€COVâ€2 infected children with distinct symptomatology. Pediatric Allergy and Immunology, 2021, 32, 1833-1842.	1.1	19
312	COVIDâ€19â€associated Guillainâ€Barre syndrome: Postinfectious alone or neuroinvasive too?. Journal of Medical Virology, 2021, 93, 6045-6049.	2.5	42
313	Generation of glucocorticoid-resistant SARS-CoV-2 TÂcells for adoptive cell therapy. Cell Reports, 2021, 36, 109432.	2.9	24
314	Neutrophilia, lymphopenia and myeloid dysfunction: a living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology. Oxford Open Immunology, 2021, 2, .	1.2	7
315	Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nature Communications, 2021, 12, 4117.	5.8	170
316	Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity. Nature Communications, 2021, 12, 4314.	5.8	29
317	Pathogenesis of the initial stages of severe COVID-19. Journal of Clinical Practice, 2021, 12, 83-102.	0.2	5

#	Article	IF	Citations
318	Impaired Priming of SARS-CoV-2-Specific Naive CD8+ T Cells in Older Subjects. Frontiers in Immunology, 2021, 12, 693054.	2.2	20
319	A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19. Journal of Basic and Clinical Physiology and Pharmacology, 2022, 33, 17-25.	0.7	10
320	Quantitative Insight into Immunopathology of SARS-CoV-2 Infection. Journal of Interferon and Cytokine Research, 2021, 41, 244-257.	0.5	0
321	A role for Tâ€cell exhaustion in Long COVIDâ€19 and severe outcomes for several categories of COVIDâ€19 patients. Journal of Neuroscience Research, 2021, 99, 2367-2376.	1.3	19
322	Network Topology of Biological Aging and Geroscience-Guided Approaches to COVID-19. Frontiers in Aging, 2021, 2, .	1.2	3
324	An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. International Immunopharmacology, 2021, 96, 107763.	1.7	35
325	Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2. Life Sciences, 2021, 277, 119503.	2.0	17
326	SARS-CoV-2-specific immune response in COVID-19 convalescent individuals. Signal Transduction and Targeted Therapy, 2021, 6, 256.	7.1	43
327	Limitations and opportunities of cancer treatment in the COVID-19 pandemic. Meditsinskiy Sovet, 2021, , 108-113.	0.1	1
329	Two-Step In Vitro Model to Evaluate the Cellular Immune Response to SARS-CoV-2. Cells, 2021, 10, 2206.	1.8	4
330	Activation or exhaustion of CD8+ T cells in patients with COVID-19. Cellular and Molecular Immunology, 2021, 18, 2325-2333.	4.8	106
331	Different T cell related immunological profiles in COVID-19 patients compared to healthy controls. International Immunopharmacology, 2021, 97, 107828.	1.7	21
332	Immunological and inflammatory profiles during acute and convalescent phases of severe/ critically ill COVID-19 patients. International Immunopharmacology, 2021, 97, 107685.	1.7	22
335	Immunological map in COVID-19. Journal of Microbiology, Immunology and Infection, 2021, 54, 547-556.	1.5	9
336	Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection. Science Advances, 2021, 7, .	4.7	27
337	The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?. Cytokine, 2021, 144, 155593.	1.4	61
338	Low CD4 T cell count predicts radiological progression in severe and critically ill COVID-19 patients: a case control study. Journal of Thoracic Disease, 2021, 13, 4723-4730.	0.6	2
339	Longitudinal changes of laboratory measurements after discharged from hospital in 268 COVID-19 pneumonia patients. Journal of X-Ray Science and Technology, 2021, 29, 1-22.	0.7	2

#	Article	IF	Citations
340	SARS-CoV-2 Infection in the Immunodeficient Host: Necessary and Dispensable Immune Pathways. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3237-3248.	2.0	4
341	Exhausting T Cells During HIV Infection May Improve the Prognosis of Patients with COVID-19. Frontiers in Cellular and Infection Microbiology, 2021, 11, 564938.	1.8	2
342	Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection. Vaccine, 2021, 39, 5940-5953.	1.7	44
343	Biomarkers of Post-COVID Depression. Journal of Clinical Medicine, 2021, 10, 4142.	1.0	52
344	The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic. Biomolecules, 2021, 11, 1372.	1.8	3
345	Structural basis of biased T cell receptor recognition of an immunodominant HLA-A2 epitope of the SARS-CoV-2 spike protein. Journal of Biological Chemistry, 2021, 297, 101065.	1.6	20
346	Immunological exhaustion: How to make a disparate concept operational?. PLoS Pathogens, 2021, 17, e1009892.	2.1	11
347	IMPACT OF COVID-19 ON MULTIPLE BODY ORGAN FAILURE: A REVIEW. International Journal of Applied Pharmaceutics, 0, , 54-59.	0.3	1
348	GAPDH, Interferon Î³, and Nitric Oxide: Inhibitors of Coronaviruses. Frontiers in Virology, 2021, 1, .	0.7	5
349	Pro-inflammatory microenvironment and systemic accumulation of CXCR3+ cell exacerbate lung pathology of old rhesus macaques infected with SARS-CoV-2. Signal Transduction and Targeted Therapy, 2021, 6, 328.	7.1	11
350	An association between immune status and chest CT scores in COVIDâ€19 patients. International Journal of Clinical Practice, 2021, 75, e14767.	0.8	3
351	Aspergillus fumigatusand aspergillosis: From basics to clinics. Studies in Mycology, 2021, 100, 100115-100115.	4.5	109
353	The Immunology of SARS-CoV-2 Infection and Vaccines in Solid Organ Transplant Recipients. Viruses, 2021, 13, 1879.	1.5	16
354	COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects. Vaccines, 2021, 9, 1082.	2.1	8
355	Machine learning algorithms utilizing blood parameters enable early detection of immunethrombotic dysregulation in COVIDâ€19. Clinical and Translational Medicine, 2021, 11, e523.	1.7	10
356	A case of varicella zoster virus meningitis following BNT162b2 mRNA COVID-19 vaccination in an immunocompetent patient. International Journal of Infectious Diseases, 2021, 113, 55-57.	1.5	15
357	SARS-CoV-2, COVID-19 and the aging immune system. Nature Aging, 2021, 1, 769-782.	5.3	208
358	Mild and Asymptomatic COVID-19 Convalescents Present Long-Term Endotype of Immunosuppression Associated With Neutrophil Subsets Possessing Regulatory Functions. Frontiers in Immunology, 2021, 12, 748097.	2.2	22

#	Article	IF	Citations
359	Increased Blood Monocytic Myeloid Derived Suppressor Cells but Low Regulatory T Lymphocytes in Patients with Mild COVID-19. Viral Immunology, 2021, 34, 639-645.	0.6	13
360	Induced pluripotent stem cell-based disease modeling and prospective immune therapy for coronavirus disease 2019. Cytotherapy, 2022, 24, 235-248.	0.3	5
361	An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial. International Immunopharmacology, 2021, 99, 107916.	1.7	12
362	Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation. Kidney International, 2021, 100, 915-927.	2.6	4
363	Understanding the immunological aspects of SARS-CoV-2 causing COVID-19 pandemic: A therapeutic approach. Clinical Immunology, 2021, 231, 108804.	1.4	5
364	Group IIA secreted phospholipase A2 is associated with the pathobiology leading to COVID-19 mortality. Journal of Clinical Investigation, 2021, 131, .	3.9	70
365	Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection. Biomedicine and Pharmacotherapy, 2021, 142, 111957.	2.5	14
366	Reduction and exhausted features of T lymphocytes under serological changes, and prognostic factors in COVID-19 progression. Molecular Immunology, 2021, 138, 121-127.	1.0	32
367	Comprehensive Laboratory Data Analysis to Predict the Clinical Severity of Coronavirus Disease 2019 in 1,952 Patients in Daegu, Korea. Annals of Laboratory Medicine, 2022, 42, 24-35.	1.2	12
368	Structural assessment of SARS-CoV2 accessory protein ORF7a predicts LFA-1 and Mac-1 binding potential. Bioscience Reports, 2021, 41, .	1.1	20
369	Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact. Immunotherapy Advances, 2021, 1, .	1.2	14
370	SARS-CoV-2-Specific T Cell Responses in Patients with COVID-19 and Unexposed Individuals. Immune Network, 2021, 21, e2.	1.6	12
371	Current Understanding of Leukocyte Phenotypic and Functional Modulation During Extracorporeal Membrane Oxygenation: A Narrative Review. Frontiers in Immunology, 2020, 11, 600684.	2.2	14
372	The immune dysregulations in COVID-19: Implications for the management of rheumatic diseases. Modern Rheumatology, 2021, 31, 927-932.	0.9	4
373	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. Molecular Biomedicine, 2021, 2, 1.	1.7	20
374	SARS-CoV-2-Associated T-Cell Responses in the Presence of Humoral Immunodeficiency. International Archives of Allergy and Immunology, 2021, 182, 195-209.	0.9	39
375	Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. Journal of Clinical Investigation, 2021, 131, .	3.9	103
376	Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2â€“reactive CD8 ⁺ T cells. Science Immunology, 2021, 6, .	5.6	185

#	Article	IF	Citations
377	Severe SARSâ€CoVâ€2 patients develop a higher specific Tâ€cell response. Clinical and Translational Immunology, 2020, 9, e1217.	1.7	31
378	Cellâ€mediated immunity to SARSâ€CoVâ€2. Pediatric Investigation, 2020, 4, 281-291.	0.6	21
379	Host Immune Response and Immunobiology of Human SARS-CoV-2 Infection. Medical Virology, 2020, , 43-53.	2.1	60
380	Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review. Clinical Rheumatology, 2020, 39, 2031-2037.	1.0	9
381	Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19. Signal Transduction and Targeted Therapy, 2020, 5, 294.	7.1	62
382	In-depth blood proteome profiling analysis revealed distinct functional characteristics of plasma proteins between severe and non-severe COVID-19 patients. Scientific Reports, 2020, 10, 22418.	1.6	80
383	SARS-CoV-2 reinfection and implications for vaccine development. Human Vaccines and Immunotherapeutics, 2020, 16, 3061-3073.	1.4	54
384	T cell phenotypes in COVID-19 - a living review. Oxford Open Immunology, 2021, 2, iqaa007.	1.2	19
385	The Impact of SARS-CoV-2 on the Human Immune System and Microbiome. Infectious Microbes & Diseases, 2021, 3, 14-21.	0.5	11
386	A Peptide-Based Checkpoint Immunomodulator Alleviates Immune Dysfunction in Murine Polymicrobial Sepsis. Shock, 2021, 55, 806-815.	1.0	15
425	Tunicate Swarm-Based Black Hole Entropic Fuzzy Clustering for Data Clustering using COVID Data. , 2020, , .		2
426	Herpes zoster might be an indicator for latent <scp>COVID</scp> 19 infection. Dermatologic Therapy, 2020, 33, e13666.	0.8	79
427	Footprint of the COVID-19 Pandemic in India: A Study of Immune Landscape and Other Factors Shielding Mortality. Analytical Cellular Pathology, 2020, 2020, 1-12.	0.7	2
428	COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight, 2020, 5, .	2.3	412
429	Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI Insight, 2020, 5, .	2.3	245
430	High levels of SARS-CoV-2â€“specific T cells with restricted functionality in severe courses of COVID-19. JCI Insight, 2020, 5, .	2.3	97
431	COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes. Journal of Clinical Investigation, 2020, 130, 6290-6300.	3.9	168
432	Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals. Journal of Clinical Investigation, 2020, 130, 6588-6599.	3.9	128

#	Article	IF	Citations
433	Are T cells helpful for COVID-19: the relationship between response and risk. Journal of Clinical Investigation, 2020, 130, 6222-6224.	3.9	8
434	Age-related susceptibility to coronavirus infections: role of impaired and dysregulated host immunity. Journal of Clinical Investigation, 2020, 130, 6204-6213.	3.9	59
435	Gilles de la Tourette Syndrome: advice in the times of COVID-19. F1000Research, 2020, 9, 257.	0.8	12
436	Gilles de la Tourette Syndrome: advice in the times of COVID-19. F1000Research, 2020, 9, 257.	0.8	12
437	Clinical features and risk factors for severe inpatients with COVID-19: A retrospective study in China. PLoS ONE, 2020, 15, e0244125.	1.1	12
438	IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 245-261.	0.2	16
439	Hemocytometric characteristics of COVID-19 patients with and without cytokine storm syndrome on the sysmex XN-10 hematology analyzer. Clinical Chemistry and Laboratory Medicine, 2021, 59, 783-793.	1.4	26
440	Why does COVID-19 disproportionately affect older people?. Aging, 2020, 12, 9959-9981.	1.4	708
441	Immunometabolism at the cornerstone of inflammaging, immunosenescence, and autoimmunity in COVID-19. Aging, 2020, 12, 26263-26278.	1.4	25
442	Pandemic of Infectious Diseases due to New Etiological Agents Predisposing Factors, Case study of COVID19 and Control Measures. International Journal of Current Microbiology and Applied Sciences, 2020, 9, 3424-3457.	0.0	1
443	The Loss of Bcl-6 Expressing T Follicular Helper Cells and the Absence of Germinal Centers in COVID-19. SSRN Electronic Journal, 2020, , 3652322.	0.4	20
444	A Review on Biochemical and Immunological Biomarkers used for Laboratory Diagnosis of SARS-CoV-2 (COVID -19). Open Microbiology Journal, 2020, 14, 290-296.	0.2	7
445	Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques. Zoological Research, 2020, 41, 503-516.	0.9	60
446	Features of the development of the COVID-19 pandemic. Medico-Biological and Socio-Psychological Issues of Safety in Emergency Situations, 2020, , 16-26.	0.2	2
447	Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Science Alliance, 2021, 4, e202000955.	1.3	56
448	Prospects for Using the ELISPOT Technological Platform as Part of Anti-Epidemic Measures Against the New Coronavirus Infection COVID-19. BIOpreparations Prevention Diagnosis Treatment, 2020, 20, 146-158.	0.2	8
449	Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses, 2021, 13, 26.	1.5	26
450	Immune-checkpoint inhibitors from cancer to COVIDâ€'19: A promising avenue for the treatment of patients with COVIDâ€'19 (Review). International Journal of Oncology, 2020, 58, 145-157.	1.4	55

#	Article	IF	Citations
451	Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses. Journal of Microbiology and Biotechnology, 2020, 30, 1109-1115.	0.9	12
452	Ocular manifestation, comorbidities, and detection of severe acute respiratory syndrome-coronavirus 2 from conjunctiva in coronavirus disease 2019: A systematic review and meta-analysis. Taiwan Journal of Ophthalmology, 2020, 10, 153.	0.3	19
453	Immunological aspects of COVID-19: What do we know?. World Journal of Biological Chemistry, 2020, 11, 14-29.	1.7	30
454	Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 353-367.	0.2	33
455	SARS-CoV-2: A Piece of Bad News. Medeniyet Medical Journal, 2020, 35, 151-160.	0.4	4
456	Post-transplant immunosuppression and COVID-19: From a double whammy to a mixed blessing. World Journal of Transplantation, 2020, 10, 267-276.	0.6	6
457	Cardiovascular disease during the COVID-19 pandemic: Think ahead, protect hearts, reduce mortality. Cardiology Journal, 2020, 27, 616-624.	0.5	18
458	A Comprehensive Review of Severe Acute Respiratory Syndrome Coronavirus 2. Cureus, 2020, 12, e7943.	0.2	12
459	The predictive role of lymphocyte subsets and laboratory measurements in COVID-19 disease: a retrospective study. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662110497.	1.0	8
460	When Immunity Kills: The Lessons of SARS-CoV-2 Outbreak. Frontiers in Immunology, 2021, 12, 692598.	2.2	7
461	Transcriptomic characteristics and impaired immune function of patients who retest positive for SARS-CoV-2 RNA. Journal of Molecular Cell Biology, 2021, 13, 748-759.	1.5	10
462	T cell immunity to SARS-CoV-2. Seminars in Immunology, 2021, 55, 101505.	2.7	55
463	S100A8/A9 in COVID-19 pathogenesis: Impact on clinical outcomes. Cytokine and Growth Factor Reviews, 2022, 63, 90-97.	3.2	39
464	The immune checkpoints storm in COVIDâ€19: Role as severity markers at emergency department admission. Clinical and Translational Medicine, 2021, 11, e573.	1.7	13
465	The link between Toxoplasma gondii infections and higher mortality in COVID-19 patients having schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 167-168.	1.8	9
466	Elevated Levels of Neutrophil Activated Proteins, Alpha-Defensins (DEFA1), Calprotectin (S100A8/A9) and Myeloperoxidase (MPO) Are Associated With Disease Severity in COVID-19 Patients. Frontiers in Cellular and Infection Microbiology, 2021, 11, 751232.	1.8	28
467	Cancer and Covid-19: Collectively catastrophic. Cytokine and Growth Factor Reviews, 2022, 63, 78-89.	3.2	10
468	Immunotherapy of multisystem inflammatory syndrome in children (MIS-C) following COVID-19 through mesenchymal stem cells. International Immunopharmacology, 2021, 101, 108217.	1.7	18

#	Article	IF	Citations
469	An overview of the recent findings of cell-based therapies for the treatment and management of COVID-19. International Immunopharmacology, 2021, 101, 108226.	1.7	1
470	The quest continues for perfect COVID-19 vaccine. Indian Journal of Medical Research, 2020, 153, 1-6.	0.4	2
471	Human immune response to SARS-CoV-2: What is known? A scoping review. Infectio, 2020, 24, 26.	0.4	1
472	Imunidade na InfeÃ§Ã£o pelo SARS-CoV-2: O que Sabemos. Revista De MedicinÄƒ InternÄƒ, Neurologe, Psihiatrie, Neurochirurgie, Dermato-venerologie MedicinÃƒ InternÄƒ, 2020, 27, .	0.0	0
473	Los rankings acadÃ©micos y la distribuciÃ³n por gÃ©nero de las universidades. Revista Espanola De Documentacion Cientifica, 2020, 43, 261.	0.1	2
475	Universidades en Google: hacia un modelo de anÃ¡lisis multinivel del posicionamiento web acadÃ©mico. Revista Espanola De Documentacion Cientifica, 2020, 43, 260.	0.1	1
478	SARS-CoV-2: una nueva amenaza. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.1	0
479	A Case Series of Amoebic Liver Abscess in Patients With COVID-19 Infection. Journal of Clinical and Experimental Hepatology, 2022, 12, 1017-1020.	0.4	1
480	The Dynamic Immunological Parameter Landscape in Coronavirus Disease 2019 Patients With Different Outcomes. Frontiers in Immunology, 2021, 12, 697622.	2.2	10
482	Exploring the Mediation Effect of Awareness and Quarantine in Affecting Rate: A Study on COVID-19. SSRN Electronic Journal, 2020, , 3624017.	0.4	0
483	A brief outlook on the current emerging trends of COVID 19 vaccines. Journal of Oral and Maxillofacial Pathology, 2020, 24, 206.	0.3	0
484	History of the Discovery and Development of Biomodulina T (InmunyVitalÂ®), a Useful Immunomodulator with a Broad Range of Clinical Applications. SSRN Electronic Journal, 0, , .	0.4	2
485	Role of senescence in the chronic health consequences of COVID-19. Translational Research, 2022, 241, 96-108.	2.2	25
486	The Role of Complementary and Alternative Medicines in the Treatment and Management of COVID-19. , 0, , .		0
487	Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. Gene Reports, 2021, 25, 101417.	0.4	15
488	A Deep Look Into COVID-19 Severity Through Dynamic Changes in Blood Cytokine Levels. Frontiers in Immunology, 2021, 12, 771609.	2.2	20
489	T Cell Immunity Evaluation and Immunodominant Epitope T Cell Receptor Identification of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Glycoprotein in COVID-19 Convalescent Patients. Frontiers in Cell and Developmental Biology, 2021, 9, 696662.	1.8	5
490	Corticosteroid treatment in COVID-19 modulates host inflammatory responses and transcriptional signatures of immune dysregulation. Journal of Leukocyte Biology, 2021, 110, 1225-1239.	1.5	4

#	Article	IF	Citations
493	Haematological Manifestations of Covid-19 and Emerging Immunohaematological Therapeutic Strategies. Journal of Evolution of Medical and Dental Sciences, 2020, 9, 3489-3494.	0.1	4
494	SARS-CoV-2: a new threat. Advances in Laboratory Medicine / Avances En Medicina De Laboratorio, 2020, 1, .	0.1	0
496	Predicting the Severity of Disease Progression in COVID-19 at the Individual and Population Level: A Mathematical Model. Clinical & Experimental Pharmacology, 2021, 11, .	0.3	0
497	Innovative recombinant protein-based vaccinesÂagainst SARS-CoV-2. , 2022, , 193-211.		1
498	Integrated analysis of circulating immune cellular and soluble mediators reveals specific COVID19 signatures at hospital admission with utility for prediction of clinical outcomes. Theranostics, 2022, 12, 290-306.	4.6	11
499	Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome. Journal of Advanced Research, 2022, 40, 179-196.	4.4	75
500	PD-1 blockade counteracts postâ€“COVID-19 immune abnormalities and stimulates the antiâ€“SARS-CoV-2 immune response. JCI Insight, 2021, 6, .	2.3	51
501	SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis. Nature Communications, 2021, 12, 6602.	5.8	104
502	Impact of Chronic HIV Infection on SARS-CoV-2 Infection, COVID-19 Disease and Vaccines. Current HIV/AIDS Reports, 2022, 19, 5-16.	1.1	9
503	Complexity of immune responses in COVID-19. Seminars in Immunology, 2021, 55, 101545.	2.7	10
504	Data-driven multi-scale mathematical modeling of SARS-CoV-2 infection reveals heterogeneity among COVID-19 patients. PLoS Computational Biology, 2021, 17, e1009587.	1.5	11
505	Coronavirus Disease 2019â€“Associated Invasive Fungal Infection. Open Forum Infectious Diseases, 2021, 8, ofab510.	0.4	75
506	Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins. PLoS ONE, 2021, 16, e0258645.	1.1	13
507	Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. Translational Research, 2022, 241, 1-12.	2.2	15
508	The role of polyspecific T-cell exhaustion in severe outcomes for COVID-19 patients having latent pathogen infections such as Toxoplasma gondii. Microbial Pathogenesis, 2021, 161, 105299.	1.3	2
509	Diabetes in COVID-19 patients: challenges and possible management strategies. Egyptian Journal of Bronchology, 2021, 15, .	0.3	2
510	Oral lichen planus after COVID-19, a case report. Annals of Medicine and Surgery, 2021, 72, 103051.	0.5	11
511	The adaptation of SARS-CoV-2 to humans. Memorias Do Instituto Oswaldo Cruz, 2022, 116, e210127.	0.8	4

#	Article	IF	Citations
512	ASSOCIATION BETWEEN LEUKOCYTES COUNT AND THE SEVERITY OF COVID-19 INFECTION. WiadomoÅ›ci Lekarskie, 2021, 74, 2417-2422.	0.1	0
513	COVID-19-Induced Cardiovascular Damage Differs from other Prevalent Viruses. Cardiology Plus, 2021, 6, 231-245.	0.2	7
514	Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants. Microbiology Spectrum, 2022, 10, e0150421.	1.2	17
515	NK cells at the crossroads in COVID-19: a question of timing. Ciencia, TecnologÃa Y Salud, 2020, 7, 309-324.	0.0	1
516	Genes implicados en la gravedad de la infecciÃ³n por SARS-cov- 2. Revista Vive, 2021, 4, 305-318.	0.1	0
517	Differential diagnosis of states of operability in young people who have had COVID-19 infection. IzvestiÃ¢ Rossijskoj Voenno-medicinskoj Akademii, 2021, 40, 69-75.	0.1	0
518	Single-cell immunology of SARS-CoV-2 infection. Nature Biotechnology, 2022, 40, 30-41.	9.4	78
519	Dynamics of Peripheral Blood T-lymphocytes Have Predictive Values for the Clinical Outcome of COVID-19 Patients in Intensive Care Unit. BMC Clinical Pathology, 2022, 15, 2632010X2110728.	0.7	0
520	Postmortem high-dimensional immune profiling of severe COVID-19 patients reveals distinct patterns of immunosuppression and immunoactivation. Nature Communications, 2022, 13, 269.	5.8	16
521	Vitamin D can reduce severity in COVID-19 through regulation of PD-L1. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 487-494.	1.4	9
522	Comprehensive Flow Cytometry Profiling of the Immune System in COVID-19 Convalescent Individuals. Frontiers in Immunology, 2021, 12, 793142.	2.2	13
523	Treatment of a full-thickness macular hole and retinal detachment secondary to toxoplasma chorioretinitis that developed shortly after COVID-19: A case report. Journal Francais D'Ophtalmologie, 2022, 45, 446-451.	0.2	3
525	Synergistic Action of Immunotherapy and Nanotherapy against Cancer Patients Infected with SARS-CoV-2 and the Use of Artificial Intelligence. Cancers, 2022, 14, 213.	1.7	0
526	The transcription factor Eomes promotes expression of inhibitory receptors on hepatic CD8⁺ T cells during HBV persistence. FEBS Journal, 2022, 289, 3241-3261.	2.2	6
527	COVIDâ€19 immunopathology with emphasis on Th17 response and cellâ€based immunomodulation therapy: Potential targets and challenges. Scandinavian Journal of Immunology, 2022, 95, e13131.	1.3	19
528	Persistent T-Cell Reactivity in a Seronegative Patient after SARS-CoV-2 Infection and One Vaccination. Vaccines, 2022, 10, 114.	2.1	3
530	T cell apoptosis characterizes severe Covid-19 disease. Cell Death and Differentiation, 2022, 29, 1486-1499.	5.0	90
531	Prognostic factors for predicting severity and mortality in hospitalized COVIDâ€19 patients. Journal of Clinical Laboratory Analysis, 2022, , e24216.	0.9	7

#	Article	IF	Citations
532	Correlation of Neutrophil to Lymphocyte Ratio with Interleukin-10 in Diagnosis and Monitoring of Coronavirus Disease-19 Patients. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 63-66.	0.1	0
533	Immune dynamics of SARS-CoV-2 virus evolution. International Journal of Molecular and Immuno Oncology, 0, 7, 3-15.	0.0	2
534	Platelets modulate CD4⁺ Tâ€cell function in COVIDâ€19 through a PDâ€L1 dependent mechanism. British Journal of Haematology, 2022, 197, 283-292.	1.2	5
535	Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19. Frontiers in Immunology, 2021, 12, 801410.	2.2	6
536	Potential impact of combined influenza and pneumococcal vaccines on the severity of respiratory illness in COVID-19 infection among type 2 diabetic patients. Clinical and Experimental Medicine, 2022, , 1.	1.9	2
538	Clinical and antibody characteristics reveal diverse signatures of severe and non-severe SARS-CoV-2 patients. Infectious Diseases of Poverty, 2022, 11, 15.	1.5	16
539	Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity. Journal of Infection and Public Health, 2022, 15, 277-288.	1.9	21
540	Pregnant Women Develop a Specific Immunological Long-Lived Memory Against SARS-COV-2. Frontiers in Immunology, 2022, 13, 827889.	2.2	5
541	Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 633-636.e3.	2.0	6
542	Peculiarities of the T Cell Immune Response in COVID-19. Vaccines, 2022, 10, 242.	2.1	24
543	In Patients with Severe COVID-19, the Profound Decrease in the Peripheral Blood T-Cell Subsets Is Correlated with an Increase of QuantiFERON-TB Gold Plus Indeterminate Rates and Reflecting a Reduced Interferon-Gamma Production. Life, 2022, 12, 244.	1.1	6
544	Thromboâ€inflammatory biomarkers and Dâ€dimer in a biracial cohort study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12632.	1.0	3
547	Increased Kynurenine Indicates a Fatal Course of COVID-19. Antioxidants, 2021, 10, 1960.	2.2	23
548	Allelic variation in class I HLA determines CD8 T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2. Science Immunology, 2021, , eabk3070.	5.6	10
549	A Case Report of Varicella Zoster Meningitis as Co-Infection With Breakthrough COVID-19 in an Immunocompetent Patient. Journal of Korean Medical Science, 2022, 37, e61.	1.1	4
550	Molecular and Cellular Mechanisms of M. tuberculosis and SARS-CoV-2 Infectionsâ€"Unexpected Similarities of Pathogenesis and What to Expect from Co-Infection. International Journal of Molecular Sciences, 2022, 23, 2235.	1.8	9
551	Significance of Immune Status of SARS-CoV-2 Infected Patients in Determining the Efficacy of Therapeutic Interventions. Journal of Personalized Medicine, 2022, 12, 349.	1.1	3
552	SARS-CoV-2-specific T cells generated for adoptive immunotherapy are capable of recognizing multiple SARS-CoV-2 variants. PLoS Pathogens, 2022, 18, e1010339.	2.1	13

#	Article	IF	Citations
553	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Signal Transduction and Targeted Therapy, 2022, 7, 57.	7.1	34
554	T cell responses to SARS-CoV-2 in humans and animals. Journal of Microbiology, 2022, 60, 276-289.	1.3	8
555	Ameliorating effects of probiotics on alterations in iron homeostasis and inflammation in COVID-19. Molecular Biology Reports, 2022, 49, 5153-5163.	1.0	4
556	Increased Risk of Herpes Zoster in Adults â‰¥50 Years Old Diagnosed With COVID-19 in the United States. Open Forum Infectious Diseases, 2022, 9, ofac118.	0.4	27
557	Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review. Frontiers in Immunology, 2022, 13, 835104.	2.2	28
558	Activated CD8+CD38+ Cells Are Associated With Worse Clinical Outcome in Hospitalized COVID-19 Patients. Frontiers in Immunology, 2022, 13, 861666.	2.2	8
559	Ethnicity-Specific Features of COVID-19 Among Arabs, Africans, South Asians, East Asians, and Caucasians in the United Arab Emirates. Frontiers in Cellular and Infection Microbiology, 2021, 11, 773141.	1.8	7
560	COVID-19: impact on Public Health and hypothesis-driven investigations on genetic susceptibility and severity. Immunogenetics, 2022, 74, 381-407.	1.2	5
561	Up-regulated serum levels of soluble CD25 and soluble CD163 in pediatric patients with SARS-CoV-2. European Journal of Pediatrics, 2022, 181, 2299-2309.	1.3	6
562	A urinary proteomic landscape of COVID-19 progression identifies signaling pathways and therapeutic options. Science China Life Sciences, 2022, 65, 1866-1880.	2.3	12
564	CD8+ T Cell Senescence: Lights and Shadows in Viral Infections, Autoimmune Disorders and Cancer. International Journal of Molecular Sciences, 2022, 23, 3374.	1.8	25
565	Recombinant human interleukin-7 reverses T cell exhaustion ex vivo in critically ill COVID-19 patients. Annals of Intensive Care, 2022, 12, 21.	2.2	10
566	Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B2 receptor antagonism. Journal of Molecular Medicine, 2022, 100, 613-627.	1.7	5
567	Molecular and Clinical Prognostic Biomarkers of COVID-19 Severity and Persistence. Pathogens, 2022, 11, 311.	1.2	16
568	Inhibitory Immune Checkpoint Receptors and Ligands as Prognostic Biomarkers in COVID-19 Patients. Frontiers in Immunology, 2022, 13, 870283.	2.2	14
569	Hematopoietic responses to SARS-CoV-2 infection. Cellular and Molecular Life Sciences, 2022, 79, 187.	2.4	29
570	Metabolic programs tailor TÂcell immunity in viral infection, cancer, and aging. Cell Metabolism, 2022, 34, 378-395.	7.2	41
571	Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. Stem Cell Research and Therapy, 2022, 13, 122.	2.4	29

#	Article	IF	Citations
572	Dysfunctional State of T Cells or Exhaustion During Chronic Viral Infections and COVID-19: A Review. Viral Immunology, 2022, 35, 284-290.	0.6	5
573	Characterization of memory T cell subsets and common Î³â^'chain cytokines in convalescent COVID-19 individuals. Journal of Leukocyte Biology, 2022, 112, 201-212.	1.5	15
574	SARS-CoV-2-Specific and Functional Cytotoxic CD8 Cells in Primary Antibody Deficiency: Natural Infection and Response to Vaccine. Journal of Clinical Immunology, 2022, 42, 914-922.	2.0	16
575	CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancerâ€"Clinical Perspectives. Frontiers in Immunology, 2022, 13, 864298.	2.2	11
576	Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression. Heliyon, 2022, 8, e09230.	1.4	16
577	SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. Nature Immunology, 2022, 23, 781-790.	7.0	116
578	Stratification of COVID-19 patients based on quantitative immune-related gene expression in whole blood. Molecular Immunology, 2022, 145, 17-26.	1.0	4
579	Up-regulated serum levels of interleukin (IL)-17A and IL-22 in Egyptian pediatric patients with COVID-19 and MIS-C: Relation to the disease outcome. Cytokine, 2022, 154, 155870.	1.4	8
580	A multi-tissue study of immune gene expression profiling highlights the key role of the nasal epithelium in COVID-19 severity. Environmental Research, 2022, 210, 112890.	3.7	23
581	The immunologic response to severe acute respiratory syndrome coronavirus 2. Allergy and Asthma Proceedings, 2021, 42, 495-505.	1.0	5
582	Inhibitory Immune Checkpoint Molecules and Exhaustion of T cells in COVID-19. Physiological Research, 2021, 70, S227-S247.	0.4	13
583	Interferon Gamma Release Assay Mitogen Responses in COVID-19. Infectious Diseases in Clinical Practice, 2022, 30, .	0.1	3
585	An update on host immunity correlates and prospects of re-infection in COVID-19. International Reviews of Immunology, 2022, 41, 367-392.	1.5	9
587	Binding of phosphatidylserineâ€positive microparticles by PBMCs classifies disease severity in COVIDâ€19 patients. Journal of Extracellular Vesicles, 2021, 10, e12173.	5.5	19
588	SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases. Journal of Translational Autoimmunity, 2022, 5, 100154.	2.0	12
589	SARS-CoV-2 productively infects primary human immune system cells in vitro and in COVID-19 patients. Journal of Molecular Cell Biology, 2022, 14, .	1.5	26
590	Risk factors of the severe course and fatal outcome in COVID-19. Physical and Rehabilitation Medicine Medical Rehabilitation, 2022, 4, 14-36.	0.1	11
591	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)â€"Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study. Clinical Infectious Diseases, 2022, 75, e1-e9.	2.9	25

#	Article	IF	Citations
592	The Role of Immune Regulatory Molecules in COVID-19. Viral Immunology, 2022, 35, 359-364.	0.6	4
593	Immune features of COVID-19 convalescent individuals revealed by a single-cell RNA sequencing. International Immunopharmacology, 2022, 108, 108767.	1.7	8
604	Immunodeficiency Should Be Excluded in Patients With Recurrent Viral Meningitis and Breakthrough COVID-19. Journal of Korean Medical Science, 2022, 37, e161.	1.1	0
605	Spectrum of herpetic eye disease during COVID-19 pandemic. Kerala Journal of Ophthalmology, 2022, 34, 47.	0.1	0
606	QUANTITATIVE AND QUALITATIVE COMPOSITION OF LYMPHOCYTE POPULATIONS AND SUBSETS IN PATIENTS WITH VARYING SEVERITY OF A NEW CORONAVIRUS INFECTION. Russian Journal of Infection and Immunity, 0, , .	0.2	0
607	T-Cell Subsets and Interleukin-10 Levels Are Predictors of Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 2022, 9, 852749.	1.2	7
608	Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic. Osong Public Health and Research Perspectives, 2022, 13, 84-100.	0.7	0
609	Time-Dependent Increase in Susceptibility and Severity of Secondary Bacterial Infections During SARS-CoV-2. Frontiers in Immunology, 2022, 13, .	2.2	11
610	Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. Frontiers in Immunology, 2022, 13, .	2.2	2
611	Persistent viral RNA shedding of SARS-CoV-2 is associated with delirium incidence and six-month mortality in hospitalized COVID-19 patients. GeroScience, 2022, 44, 1241-1254.	2.1	12
612	Immune response in COVID-19: what is next?. Cell Death and Differentiation, 2022, 29, 1107-1122.	5.0	69
613	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?. Expert Review of Vaccines, 2022, 21, 1071-1086.	2.0	3
614	Cytokine storm promoting T cell exhaustion in severe COVID-19 revealed by single cell sequencing data analysis. Precision Clinical Medicine, 2022, 5, .	1.3	11
615	Epigenetic Activation of Antiviral Sensors and Effectors of Interferon Response Pathways During SARS-CoV-2 Infection. SSRN Electronic Journal, 0, , .	0.4	0
616	Ð"Ð†ÐÐ"ÐÐžÐ¡Ð¢Ð˜Ð§ÐÐ•Ð¢Ð¾ÐŸÐÐžÐ"ÐÐžÐ¡Ð¢Ð˜Ð§ÐÐ•Ð—ÐÐÐ§Ð£Ð©Ð†Ð¡Ð¯ Ð†ÐœÐ£ÐÐžÐ›ÐžÐ"Ð†Ð§ÐÐ˜Ð¥ ÐœÐÐÐšÐ•Ð		
619	Simultaneous occurrence of knee septic arthritis and coronavirus disease 2019 (COVID-19): A case report. Egyptian Rheumatologist, 2022, , .	0.5	1
620	Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors. Frontiers in Immunology, 0, 13, .	2.2	10
621	Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity. Cells, 2022, 11, 1978.	1.8	10

#	Article	IF	Citations
622	Racial and ethnic disparities in coronavirus disease 2019 disease incidence independent of comorbidities, among people with HIV in the United States. Aids, 2022, 36, 1095-1103.	1.0	10
623	Antigenic Determinants of SARS-CoV-2-Specific CD4+ T Cell Lines Reveals M Protein-Driven Dysregulation of Interferon Signaling. Frontiers in Immunology, 0, 13, .	2.2	2
624	Study of ACE2 gene expression and evaluated some cellular and humoral immunity parameters of COVID-19 patients in Ramadi City. International Journal of Health Sciences, 0, , 2487-2499.	0.0	0
625	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Frontiers in Immunology, 0, 13, .	2.2	28
626	COVID-19 disease and autoimmune disorders: A mutual pathway. World Journal of Methodology, 2022, 12, 200-223.	1.1	12
627	Immune Cells Profiles In The Peripheral Blood Of Patients With Moderate To Severe COVID-19 And Healthy Subjects With and Without Vaccination With The Pfizer-BioNTech mRNA Vaccine. Frontiers in Immunology, 0, 13, .	2.2	4
628	A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. Pharmaceutical Research, 2022, 39, 2119-2134.	1.7	10
629	In Vitro Exposure of Primary Human T Cells and Monocytes to Polyclonal Stimuli Reveals a Basal Susceptibility to Display an Impaired Cellular Immune Response and Develop Severe COVID-19. Frontiers in Immunology, 0, 13, .	2.2	2
630	Short and long-term immune changes in different severity groups of COVID-19 disease. International Journal of Infectious Diseases, 2022, 122, 776-784.	1.5	4
631	A comprehensive evaluation of the immune system response and type-I Interferon signaling pathway in hospitalized COVID-19 patients. Cell Communication and Signaling, 2022, 20, .	2.7	19
632	COVID-19: Clinical, Immunological, and Image Findings from Infection to Post-COVID Syndrome. , 2022, , 76-98.		0
633	Epigenetic activation of antiviral sensors and effectors of interferon response pathways during SARS-CoV-2 infection. Biomedicine and Pharmacotherapy, 2022, 153, 113396.	2.5	5
634	Long COVID and the cardiovascular systemâ€"elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases. Cardiovascular Research, 2023, 119, 336-356.	1.8	53
635	Singleâ€cell transcriptomic atlas reveals distinct immunological responses between COVIDâ€19 vaccine and natural SARSâ€CoVâ€2 infection. Journal of Medical Virology, 2022, 94, 5304-5324.	2.5	17
636	Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic. Cancers, 2022, 14, 3598.	1.7	7
637	Antitumor immunotherapy and COVID-19 in cancer patients. , 2022, 21, 10-18.	0.3	0
638	SARS-CoV-2 Specific Immune Response and Inflammatory Profile in Advanced HIV-Infected Persons during a COVID-19 Outbreak. Viruses, 2022, 14, 1575.	1.5	7
639	In vitro and in vivo pharmacodynamic activity of the new compound XC221GI in models of the viral inflammation of the respiratory tract. Microbiology Independent Research Journal, 0, 9, .	0.2	4

#	Article	IF	Citations
640	Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19. Nature, 2022, 609, 801-807.	13.7	65
642	The immune response as a doubleâ€edged sword: The lesson learnt during the <scp>COVID</scp>â€19 pandemic. Immunology, 2022, 167, 287-302.	2.0	15
643	High baseline expression of IL-6 and IL-10 decreased CCR7 B cells in individuals with previous SARS-CoV-2 infection during BNT162b2 vaccination. Frontiers in Immunology, 0, 13, .	2.2	0
644	COVID-19 and pregnancy: clinical outcomes; mechanisms, and vaccine efficacy. Translational Research, 2023, 251, 84-95.	2.2	14
645	The striking mimics between COVID-19 and malaria: A review. Frontiers in Immunology, 0, 13, .	2.2	9
646	Cellular heterogeneity in disease severity and clinical outcome: Granular understanding of immune response is key. Frontiers in Immunology, 0, 13, .	2.2	3
647	Identification of Novel Therapeutic Candidates Against SARS-CoV-2 Infections: An Application of RNA Sequencing Toward mRNA Based Nanotherapeutics. Frontiers in Microbiology, 0, 13, .	1.5	4
648	Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity. Journal of Immunology Research, 2022, 2022, 1-9.	0.9	9
649	COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses. Frontiers in Immunology, 0, 13, .	2.2	3
650	Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study. International Journal of Infectious Diseases, 2022, 123, 97-103.	1.5	5
651	The Role of Lymphocyte Subsets, PD-1, and FAS (CD95) in COVID-19 Cancer Patients. Viral Immunology, 0, , .	0.6	1
652	Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19. Clinical Immunology, 2022, 244, 109093.	1.4	9
653	The Modulatory Action of C-Vx Substance on the Immune System in COVID-19. Emerging Microbes and Infections, 0, , 1-28.	3.0	2
655	T cells in SARS-CoV-2 infection and vaccination. , 2022, 10, 251513552211150.	1.4	4
656	SARS-CoV-2 and Co-morbidities. , 2022, , 1-28.		0
657	Low quantity and quality of anti-spike humoral response is linked to CD4 T-cell apoptosis in COVID-19 patients. Cell Death and Disease, 2022, 13, .	2.7	5
658	Distinct Immune Phenotypes and Cytokine Profiles in Children with Differing Severity of COVID-19. Pediatric Infectious Disease Journal, 2022, 41, 919-926.	1.1	2
659	Developing dendritic cell for SARS-CoV-2 vaccine: Breakthrough in the pandemic. Frontiers in Immunology, 0, 13, .	2.2	2

#	Article	IF	Citations
660	Combined metabolic analyses for the biosynthesis pathway of l-threonine in Escherichia coli. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	3
661	Evaluating immunohaematological profile among COVID-19 active infection and recovered patients in Ghana. PLoS ONE, 2022, 17, e0273969.	1.1	0
662	PD-1/PD-L1 blockade abrogates a dysfunctional innate-adaptive immune axis in critical Î²-coronavirus disease. Science Advances, 2022, 8, .	4.7	14
663	Lycopene: a therapeutic strategy against coronavirus disease 19 (COVID- 19). Inflammopharmacology, 2022, 30, 1955-1976.	1.9	11
664	COVIDâ€19 immunopathology: From acute diseases to chronic sequelae. Journal of Medical Virology, 2023, 95, .	2.5	24
665	SARS-CoV-2-specicific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4+ T-cell help and negatively correlated with Alphacoronavirus-specific antibody titer. Immunology Letters, 2022, 251-252, 38-46.	1.1	2
666	Rethinking sepsis after a two-year battle with COVID-19. , 2022, 19, 1317-1318.		5
667	Surface translocation of ACE2 and TMPRSS2 upon TLR4/7/8 activation is required for SARS-CoV-2 infection in circulating monocytes. Cell Discovery, 2022, 8, .	3.1	11
668	Non-coding RNAs: Key players in T cell exhaustion. Frontiers in Immunology, 0, 13, .	2.2	2
669	Immune checkpoint alterations and their blockade in COVID-19 patients. Blood Science, 2022, 4, 192-198.	0.4	2
670	Saliva metabolomic profile of COVID-19 patients associates with disease severity. Metabolomics, 2022, 18, .	1.4	15
671	Neuroâ€“Immune Interactions in Severe COVID-19 Infection. Pathogens, 2022, 11, 1256.	1.2	1
672	Adaptive immunity to SARS-CoV-2 infection: A systematic review. Frontiers in Immunology, 0, 13, .	2.2	18
673	Immune system disturbances after a new coronavirus infection COVID-19. Jurnal Infektologii, 2022, 14, 26-37.	0.1	4
674	Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities. Vaccines, 2022, 10, 1673.	2.1	1
675	CD8+ T-cell immune escape by SARS-CoV-2 variants of concern. Frontiers in Immunology, 0, 13, .	2.2	8
676	Zebrafish models of COVID-19. FEMS Microbiology Reviews, 2023, 47, .	3.9	6
677	Identification of COVID-19 severity biomarkers based on feature selection on single-cell RNA-Seq data of CD8+ T cells. Frontiers in Genetics, 0, 13, .	1.1	5

#	Article	IF	Citations
678	Mid-upper arm circumference as a substitute for body mass index in the assessment of nutritional status among adults in eastern Sudan. BMC Public Health, 2022, 22, .	1.2	9
679	Influence of SARS-COV-2 Infection on Cytokine Production by Mitogen-Stimulated Peripheral Blood Mononuclear Cells and Neutrophils in COVID-19 Intensive Care Unit Patients. Microorganisms, 2022, 10, 2194.	1.6	1
680	Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities. Clinical Immunology, 2022, 245, 109177.	1.4	12
681	Role of SARS-CoV-2-induced cytokine storm in multi-organ failure: Molecular pathways and potential therapeutic options. International Immunopharmacology, 2022, 113, 109428.	1.7	22
682	Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with mild/asymptomatic COVID-19. Clinical Immunology, 2023, 246, 109209.	1.4	14
683	First case series and literature review of coronavirus disease 2019 (COVID-19) associated pulmonary tuberculosis in Southeast Asia: Challenges and opportunities. Journal of Infection and Public Health, 2023, 16, 80-89.	1.9	0
684	Immunosenescence and inflamm-ageing in COVID-19. Ageing Research Reviews, 2023, 84, 101818.	5.0	18
685	Antitumor Immunotherapy: Effect of COVID-19 in Cancer Patients. , 2023, , 251-266.		0
686	Analysis of CT signs, radiomic features and clinical characteristics for delta variant COVID-19 patients with different vaccination status. BMC Medical Imaging, 2022, 22, .	1.4	0
687	Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives. Frontiers in Immunology, 0, 13, .	2.2	14
688	Identification of Transcriptome Biomarkers for Severe COVID-19 with Machine Learning Methods. Biomolecules, 2022, 12, 1735.	1.8	3
689	Different Formulations of Inactivated SARS-CoV-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses. Viral Immunology, 2022, 35, 663-672.	0.6	2
690	Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer. Frontiers in Immunology, 0, 13, .	2.2	4
691	Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?. Drugs, 2023, 83, 1-36.	4.9	4
692	Challenges of COPD Patients during the COVID-19 Pandemic. Pathogens, 2022, 11, 1484.	1.2	0
693	Concurrent infections of cells by two pathogens can enable a reactivation of the first pathogen and the second pathogen's accelerated T-cell exhaustion. Heliyon, 2022, 8, e11371.	1.4	2
694	Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities. International Journal of Molecular Sciences, 2022, 23, 15122.	1.8	1
695	Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell immunoprofiling. Frontiers in Immunology, 0, 13, .	2.2	6

#	Article	IF	Citations
697	Single-cell multiomics revealed the dynamics of antigen presentation, immune response and T cell activation in the COVID-19 positive and recovered individuals. Frontiers in Immunology, 0, 13, .	2.2	5
698	LAG-3 Contribution to T Cell Downmodulation during Acute Respiratory Viral Infections. Viruses, 2023, 15, 147.	1.5	2
699	Modeling and analyzing single-cell multimodal data with deep parametric inference. Briefings in Bioinformatics, 2023, 24, .	3.2	23
700	Tissue injury and leukocyte changes in post-acute sequelae of SARS-CoV-2: review of 2833 post-acute patient outcomes per immune dysregulation and microbial translocation in long COVID. Journal of Leukocyte Biology, 2023, 113, 236-254.	1.5	7
701	Therapeutic modulation of V Set and Ig domain-containing 4 (VSIG4) signaling in immune and inflammatory diseases. Cytotherapy, 2023, 25, 561-572.	0.3	1
703	T Cells Immunophenotyping and CD38 Overexpression as Hallmarks of the Severity of COVID-19 and Predictors of Patientsâ€™ Outcomes. Journal of Clinical Medicine, 2023, 12, 710.	1.0	2
704	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. Vaccines, 2023, 11, 101.	2.1	14
705	Severe respiratory viral infections: T-cell functions diverging from immunity to inflammation. Trends in Microbiology, 2023, 31, 644-656.	3.5	7
706	Cutaneous manifestations of <scp>COVID</scp>â€19 and <scp>COVID</scp>â€19 vaccination. Journal of Dermatology, 2023, 50, 280-289.	0.6	14
707	Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection. , 2023, , 237-262.		0
708	Unveiling the prevalence and impact of diabetes on COVID-19. , 2023, , 287-301.		0
709	Severe and mild-moderate SARS-CoV-2 vaccinated patients show different frequencies of IFNÎ³-releasing cells: An exploratory study. PLoS ONE, 2023, 18, e0281444.	1.1	3
711	Severely ill and high-risk COVID-19 patients exhibit increased peripheral circulation of CD62L+ and perforin+ T cells. Frontiers in Immunology, 0, 14, .	2.2	1
712	Immune cell population and cytokine profiling suggest age dependent differences in the response to SARS-CoV-2 infection. Frontiers in Aging, 0, 4, .	1.2	5
713	Employing T-Cell Memory to Effectively Target SARS-CoV-2. Pathogens, 2023, 12, 301.	1.2	0
714	Lung T cell response in COVID-19. Frontiers in Immunology, 0, 14, .	2.2	6
715	Functionality of immune cells in COVID-19 infection: development of cell-based therapeutics. BioImpacts, 0, , .	0.7	0
716	Role of the immune system in COVID-19 pathomorphogenesis. Genes and Cells, 2020, 15, 75-87.	0.2	0

#	Article	IF	Citations
717	Modeling and predicting the overlap of B- and T-cell receptor repertoires in healthy and SARS-CoV-2 infected individuals. PLoS Genetics, 2023, 19, e1010652.	1.5	7
718	Elevated free interleukin-18 associated with severity and mortality in prospective cohort study of 206 hospitalised COVID-19 patients. Intensive Care Medicine Experimental, 2023, 11, .	0.9	7
719	Current status in cellular-based therapies for prevention and treatment of COVID-19. Critical Reviews in Clinical Laboratory Sciences, 0, , 1-25.	2.7	0
720	Effects of COVID-19 Pandemic on Young Individuals - A Mini Review. Emirates Medical Journal, 2023, 04, .	0.3	0
721	Correlation of Lymphocyte Subpopulations, Clinical Features and Inflammatory Markers during Severe COVID-19 Onset. Pathogens, 2023, 12, 414.	1.2	4
722	The role of immune activation and antigen persistence in acute and long COVID. Journal of Investigative Medicine, 2023, 71, 545-562.	0.7	17
724	Extracorporeal Circulation-Related Immune Response. Lessons From the ICU, 2023, , 85-112.	0.1	0
725	The Dysregulated Host Response. Lessons From the ICU, 2023, , 19-34.	0.1	0
726	Association between the overall burden of comorbidity and Ct values among the older patients with Omicron infection: Mediated by inflammation. Frontiers in Immunology, 0, 14, .	2.2	1
727	Pathogen regulatory RNA usage enables chronic infections, T-cell exhaustion and accelerated T-cell exhaustion. Molecular and Cellular Biochemistry, 0, , .	1.4	0
728	Immune and ionic mechanisms mediating the effect of dexamethasone in severe COVID-19. Frontiers in Immunology, 0, 14, .	2.2	4
729	A review of cytokine-based pathophysiology of Long COVID symptoms. Frontiers in Medicine, 0, 10, .	1.2	28
730	Molecular Understanding of ACE-2 and HLA-Conferred Differential Susceptibility to COVID-19: Host-Directed Insights Opening New Windows in COVID-19 Therapeutics. Journal of Clinical Medicine, 2023, 12, 2645.	1.0	2
731	Metabolic dysregulation impairs lymphocyte function during severe SARS-CoV-2 infection. Communications Biology, 2023, 6, .	2.0	3
732	Cellular and Humoral Immune Responses to Vaccination for COVID-19 Are Negatively Impacted by Senescent T Cells: A Case Report. Vaccines, 2023, 11, 840.	2.1	1
733	Repurposed Drugs/Potential Pharmacological Agents Targeting Cytokine Release and Induction of Coagulation in COVID-19. , 2023, , 100-136.		0
750	SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors. Cell Death and Disease, 2023, 14, .	2.7	3
751	Host immune responses in COVID-19. , 2023, , 121-150.		0

#	Article	IF	Citations
759	The kinetics of inhibitory immune checkpoints during and post-COVID-19: the knowns and unknowns. Clinical and Experimental Medicine, 0, , .	1.9	0
764	COVID-19: secondary and superimposed bacterial infections. , 2023, , 183-201.		0
768	Immunomodulatory Plant Extracts and their Compounds. Evaluation of your Safety. , 2023, , 197-224.		0
787	COVID-19 pathogenesis. Progress in Molecular Biology and Translational Science, 2024, , .	0.9	0
796	Evaluation of TIM-3 gene expression in a patients with COVID-19. AIP Conference Proceedings, 2024, , .	0.3	0